학술논문
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses
Document Type
Article
Author
Source
In Vaccine July 2023
Subject
Language
ISSN
0264-410X